Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748127 | 0.88 | CSNK1D (0.31) | CSNK1D | |
| Trifluoroacetic Acid SCHEMBL20919472 | 0.86 | CSNK1D (0.39) | CSNK1DALDH1A1POLBIKBKB | |
| SCHEMBL19747589 | 0.79 | CSNK1D (0.38) | CSNK1DALDH1A1POLBHAVCR2HPGD | |
| SCHEMBL20934833 | 0.79 | CDK1 (0.38) | — | |
| SCHEMBL19748431 | 0.75 | — | — | |
| SCHEMBL19747940 | 0.75 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL20940165 | 0.75 | — | — | |
| SCHEMBL19748398 | 0.73 | CSNK1D (0.38) | CSNK1DADORA2AADORA2BADORA1 | |
| SCHEMBL19748324 | 0.71 | CSNK1D (0.32) | CSNK1DALDH1A1 | |
| SCHEMBL19766654 | 0.70 | CSNK1D (0.32) | CSNK1DADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118063470-A | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111542526-B | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-08-11 | — | — | US | disclosed |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-4006034-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11225486-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3697789-B1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| WO-2019079469-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| WO-2017223414-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | CSNK1D 117/4885ALDH1A1 1354/4885POLB 633/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | CSNK1D 143/4885ALDH1A1 1774/4885POLB 869/4885 |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | CSNK1D 1431/4885ALDH1A1 333/4885POLB 733/4885 |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | PIK3CA, PIK3CG, PIK3CD | CSNK1D 235/4885ALDH1A1 1168/4885POLB 944/4885 |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | CSNK1D 243/4885ALDH1A1 2818/4885POLB 1535/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CSNK1D 382/4885ALDH1A1 3638/4885POLB 730/4885 |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | CSNK1D 1431/4885ALDH1A1 333/4885POLB 733/4885 |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CSNK1D 382/4885ALDH1A1 3638/4885POLB 730/4885 |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | CSNK1D 382/4885ALDH1A1 3638/4885POLB 730/4885 |
| US-11225486-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | CSNK1D 1475/4885ALDH1A1 155/4885POLB 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.